LITERATURE REVIEW: NEUROLOGICAL ASPECT OF CORONAVIRUS DISEASE 2019 (COVID-19): PART II. CLINICAL MANIFESTATIONS AND DRUG INTERACTIONS

Authors

  • Arthur H.P Mawuntu Staf, Divisi Neuroinfeksi, Neuroimunologi, dan Neuro-AIDS
  • Devina C Mastari Peserta PPDS Program Pendidikan Dokter Spesialis Neurologi Bagian/KSM Neurologi Fakultas Kedokteran Universitas Sam Ratulangi/RSUP Prof. dr. R.D. Kandou Manado, Indonesia
  • Albertus T Lapian Peserta PPDS Program Pendidikan Dokter Spesialis Neurologi Bagian/KSM Neurologi Fakultas Kedokteran Universitas Sam Ratulangi/RSUP Prof. dr. R.D. Kandou Manado, Indonesia
  • Agnes K.S. Hermawan Peserta PPDS Program Pendidikan Dokter Spesialis Neurologi Bagian/KSM Neurologi Fakultas Kedokteran Universitas Sam Ratulangi/RSUP Prof. dr. R.D. Kandou Manado, Indonesia
  • Mieke A.H.N Kembuan Staf, Divisi Neuroinfeksi, Neuroimunologi, dan Neuro-AIDS

Keywords:

COVID-19, clinical manifestations, neurological manifestations, drug interactions

Abstract

Coronavirus disease 2019 (COVID-19) was first reported in China in December 2019. This novel
virus has caused a world health crisis with various clinical manifestations. Although the common
manifestations of COVID-19 infection are fever, cough, malaise, and respiratory problems, there are
increasing reports of clinical manifestations and neurological complications such as decreased
consciousness, headache, anosmia, stroke, seizures, polyneuropathy, and myopathy. The emergence
of neurological manifestations has prompted efforts to understand the COVID-19 therapies and the
potential drug interactions. Other issues discussed in other parts were pathomechanisms, drug
interactions as well as disease effects in neurology patients. Understanding this may help manage the
patient

Published

2021-06-14